Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...

When my husband, Donnie, first became sick with pulmonary fibrosis (PF), we were unsure of the road that lay before us. His diagnosis finally came after specialized blood work and video-assisted ...

With chronic kidney disease a risk for transplant recipients, columnist Sam Kirton writes about the need for more living kidney donors.

Dosing is now underway in an IPF clinical trial testing the inhaled therapy LTI-03, following the lifting of an FDA hold late last year.

Columnist Sam Kirton has developed some strategies to make the roughly 90-minute commute to his IPF doctor appointments more manageable.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...